All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma Hub

Brought to you by Scientific Education Support

Scientific Education Support

The Lymphoma Hub is an independent medical education platform, sponsored by Roche, AbbVie, BeOne, Miltenyi Biomedicine, Thermo Fisher, Nurix Therapeutics and Caribou Biosciences and supported through independent educational grants from Incyte, Bristol Myers Squibb, Pfizer and Takeda Pharmaceuticals U.S.A., Inc. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My Lymphoma Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View lymphoma & CLL content recommended for you

EHA 2023

Share:

Jun 8, 2023

X post image

11 Jun 2023

CONGRESS #EHA2023 |Efstathios Kastritis @uoaofficial discusses novel therapies for Waldenström's Macrogobulinemia. New BCL-2 inhibitors, BTK inhibitors & immunotherapies seem promising however toxicity will be crucial factor given the age, comorbidities &frailty of WM pts.
#lymsm

X post image

11 Jun 2023

CONGRESS #EHA2023 | Marco Ladetto @UniAvogadro talks about how to approach a patient with R/R follicular #lymphoma. Novel agents like T-cell engagers & rational combinations of existing treatments might further broaden therapeutic armamentarium.
#lym #lymsm @EHA_Hematology

X post image

11 Jun 2023

#EHA2023 | @Jessica_Okosun @QMBCI talks about biology, natural history & current targets in indolent #lymphoma. She emphasizes on limitations with existing targets & need for new targets with improved precision using predictive biomarkers &biology-enriched clinical trials #lymsm

X post image

11 Jun 2023

#EHA2023 |Cristina Santoro @SapienzaRoma presents retrospective study validating ThroLy & Khorana scores in predicting thrombotic events in HL. Significant association was seen between ThroLy & TE. Based on 4 specific risk factors evidenced, a new HL-ThroLy was proposed.
#lymsm

X post image

11 Jun 2023

CONGRESS #EHA2023 | @gilles_salles @MSKCancerCenter discusses a phase I/II trial of epocoritamab vs axi-cel in R/R DLBCL CAR-T naïve & eligible pts. There was no sig. difference in ORR or CR rates for CAR T-naive vs axi-cel. Results were similar for Ep vs Axi-cel #lymsm #lymphoma

X post image

11 Jun 2023

CONGRESS #EHA2023 | @DocHutchings @Rigshospitalet describes a phase II trial of glofitamab in pts with R/R LBCL. N=154. After a median FU =18.3 months, 39/59 pts who achieved CR were ongoing. Median duration of CR =24.1 months. 18-month OS rate =80% #lymsm #lymphoma

X post image

11 Jun 2023

CONGRESS #EHA2023 | Yasuhito Suehara @UNIV_TSUKUBA_JP discusses how tumor microenvironment signatures & genetic subtypes are associated with distinct outcomes in PTCL. C1 & C3, nTFHL genetic subtypes, showed differences in clinical features & survival outcomes. #lymsm #lymphoma

X post image

11 Jun 2023

#EHA2023 | Arnon Kater @amsterdamumc shares the final 7-year follow up data from the MURANO trial of VenR in R/RCLL. OS 69.6% and 51% in VenR and BR treated pts, respectively. PFS 23% VenR and 0% BR. Median PFS 23.3mo in VenR-retreated pts. #CLL #lymsm

X post image

11 Jun 2023

#EHA2023 | Petra Langerbeins @UniCologne shares the final results of the CLL12 trial on ibrutinib in treatment-naïve early stage CLL. ORR 72.5%, median OS not reached. Ibrutinib failed to demonstrate survival benefit compared with placebo. #lymsm

X post image

11 Jun 2023

What better way to finish off a weekend of inspiring and exciting presentations at #EHA2023 than with the late breaking abstract session. Many congratulations to all speakers! @EHA_Hematology #medicalcongress #lymphoma #lymsm

X post image

10 Jun 2023

CONGRESS #EHA2023 | Seung-Ah Yahng, Catholic University of Korea, presents ph III trial results showing no difference between intrathecal MTX & high-dose IV MTX for prophylaxis of CNS relapse in high-risk DLBCL pts. Both routes were tolerable.
#lymphoma #lymsm @EHA_Hematology

X post image

10 Jun 2023

CONGRESS #EHA2023 | @LeppaSM @helsinkiuni presents initial safety data from ph III POLAR BEAR trial. R-pola-mini-CHP & R-mini-CHOP had comparable safety profile & were tolerable in elderly or frail pts with DLBCL. GI events were more common in pola group.
#lymhoma #lym #lymsm

X post image

10 Jun 2023

#EHA2023 |Amira Marouf @InstitutImagine presents efficacy of aPD1 therapy in R/R extranodal NK/T cell #lymphoma. ORR was 40.5%, CR was 35% & 2-yr OS was 50.2%. Comparative analysis with historic cohort showed superiority of aPD1 compared to historical salvage therapy
#lym #lymsm

X post image

10 Jun 2023

CONGRESS|#EHA2023 Yi Zhang, Zhengzhou University Hospital presents results from the first-in-human study of CD19/BCMA dual CART GC012F for R/R B-NHL. The longest duration of remission was 14.4 months and no dose-limiting toxicities were recorded #lymphoma #lymsm #medicalcongress

X post image

10 Jun 2023

CONGRESS #EHA2023 | Philipp Berning @UK_Muenster presents a retrospective analysis on role of allo #HSCT in 135 pts with R/R NK T-cell #lymphoma. 5-yr PFS & OS were 48.6% & 52.9%, respectively. 3-yr NRM was 17.3%. MAC & RIC regimens showed similar survival.
#lym #lymsm

X post image

10 Jun 2023

CONGRESS|#EHA2023 Francois Lemonnier presents results from the ALYCANTE trial investigating axi-cel as 2nd line therapy for treatment of LBCL. CMR at 3 months was 70% vs 12% expected with SOC. OR and CR rates were 92.5% and 80%, respectively #lymphoma #lymsm #medicalcongress

X post image

10 Jun 2023

CONGRESS|#EHA2023 Matthew Frank @StanfordMed discusses the safety and efficacy of CD22 CART therapy in pts with LBCL who have relapsed after CD19 CART therapy. The ORR and CR rates were 68% and 53%, respectively #lymphoma #lymsm #medicalcongress

X post image

10 Jun 2023

CONGRESS #EHA2023 | Melina Sophie Kurte presents a health economic evaluation for transplant-ineligible R/R #DLBCL pts in Germany. RGemOx, Tafa-L and axi-cel were shown to be cost-effective treatment options.
#lymsm #medicalcongress

X post image

10 Jun 2023

#EHA2023 | Maurizio Martelli, @SapienzaRoma presents the results of the IELSG37 trial. Initial data supports the omission of mediastinal radiotherapy in PMBCL patients achieving a CMR after immunochemotherapy.
#lymsm #lymphoma

X post image

10 Jun 2023

Great location, with even better presentations. The plenary abstracts award session @EHA_Hematology conference never fails to disappoint. A massive congratulations to all winners!
#EHA2023 #medicalcongress

X post image

10 Jun 2023

CONGRESS| Not much room left in the plenary abstracts session at #EHA2023! Looking forward to the presentations on the best scoring abstracts from the whole congress #leukemia #leusm #medicalcongress

X post image

10 Jun 2023

CONGRESS #EHA2023 | @JudithTrotman1 @SydneyLHD shows analysis of the phII ROSEWOOD study of zanubrutinib + obinutuzumab in R/R follicular #lymphoma. N=217. Est OS rate at 24 months = 77.3% (zan + obin) & 71.4% (obin), with median OS =NR (zan + obin) & 34.6 months (obin). #lymsm

X post image

10 Jun 2023

CONGRESS #EHA2023 | Laurie Sehn @BCCancer presents a phase II study of mosunetuzumab in pts with R/R follicular #lymphoma. N=90. 60% achieved CR as best response: 54% achieved CR at EOT; 1 pt with a CR experienced PD in C8; & 4 pts achieved CR after EOT. #lymsm

X post image

10 Jun 2023

#EHA2023 | Stefanie Kreutmair @UZH_en presents on a systems immunology approach to define the CAR T specific immune landscape to serve as predictive biomarkers for response and toxicity in B cell lymphoma patients.
#lymphoma #lymsm

X post image

10 Jun 2023

CONGRESS #EHA2023 | Esther Oliva @GOM_rc presents SLR on use & frequency of PRO measures in RCTs for #lymphoma. Most referenced global PROM for Hodgkin lymphoma were EORTC-QLQ-C30, EQ-5D, & FACT-Neurotoxicity used in 12, 3, & 2 studies, respectively.
#lym #lymsm @EHA_Hematology

X post image

9 Jun 2023

CONGRESS|#EHA2023 Fantastic presentations and discussions from our joint Lymphoma Hub and @MM_Hub symposium discussing the ins and outs of CAR T cells in the real world chaired by Ulrich Jager #lymphoma #lymsm #multiplemyeloma #MMsm #medicalcongress

X post image

9 Jun 2023

CONGRESS| #EHA2023 Ryan Jacobs @LevineCancer presents interim data of a study investigating TNB-486 in patients with R/R FL post-3 lines of therapy. TNB-486 induces high CR rate (91%) at ≥2.4mg and a dose escalation study is set to determine RP2D #lymsm

X post image

9 Jun 2023

#EHA2023 Caron Jacobson @DanaFarber presents real-world outcomes for patients with R/R FL eligible and ineligible for the ZUMA-5 trial. Results show effectiveness (93%; 95% CI, 88-97 achieved OR) and a manageable safety profile to support broader use of axi-cel for R/R FL #lymsm

X post image

9 Jun 2023

CONGRESS| #EHA2023 @AnnaSureda5 presents results from 2 cohorts in EPCORE NH2 investigating epcoritamab+rituximab & lenalidomide in patients with R/R FL. This combination showed potent anti-tumor activity and a manageable safety profile in patients with high-risk disease #lymsm

X post image

9 Jun 2023

#EHA2023 Marco Ladetto @UniAvogadro presents clinical data and MRD analysis follow-up of FILMCL0208 trial evaluating lenalidomide post ASCT and treatment discontinuation in patients with MCL. The benefit is confined to active treatment with increased PFS post interruption#lymsm

X post image

9 Jun 2023

CONGRESS| #EHA2023 @NausheenAhmedMD describes the outcomes of a real-world analysis study evaluating brexu-cel in adult patients with R/R MCL based on prior lines of therapy. Early findings suggest outcomes of brexu-cel are consistent regardless of prior therapy #lymsm

X post image

9 Jun 2023

CONGRESS |#EHA2023 Caron Jacobson @DanaFarber presents mechanisms of resistance to CAR T-cell therapy. A hypothetical triad of tumor, systemic immune state and axi-cel attributes influence durable response. So, how do we ensure patients have a more favorable immune profile?#lymsm

X post image

9 Jun 2023

CONGRESS #EHA2023 | Andrew Davies @CR_UK covers the design of ZUMA-22 a phIII study of axi-cel vs SOC in pts with R/R follicular #lymphoma. Currently recruiting & aiming for ~230 pts. Main endpoint = PFS. 2ndary endpoints include CR, ORR, DOR, OS, EFS, safety & TTNT & QoL. #lymsm

X post image

9 Jun 2023

CONGRESS #EHA2023 |@Stelegouill @institut_curie talks through immunotherapy treatment paradigm in relapsed/refractory DLBCL. He discusses monotherapy & combination/sequential approaches with mAbs, Abs drug conjugate, CAR-T cells & bispecific Abs.
#lymphoma #lymsm @EHA_Hematology

X post image

9 Jun 2023

CONGRESS #EHA2023| @LeppaSM @helsinkiuni talks on role of ctDNA in tracking behavior of DLBCL. ctDNA is a versatile biomarker, correlates with other measures of tumor burden, reveals heterogeneity, measures MRD & can be detected prior to relapse.
#lymphoma #lymsm @EHA_Hematology

X post image

9 Jun 2023

CONGRESS| #EHA2023| Mamiko Sakata-Yanagimoto discusses predispositions affecting incidence of mature T/NK-cell neoplasms. EBV and HTLV-1 infections are associated with mature T/NK-cell neoplasms in East Asia whilst germline variants require further study to determine this. #lymsm

X post image

9 Jun 2023

CONGRESS| #EHA2023 | Tarec El-Galaly discusses the prevalence of lymphomas globally in context of environment and genetics. In future, more studies are required to uncover the biological differences in DLBCL and understand differences in the diagnostic work-up. #lymsm

X post image

9 Jun 2023

CONGRESS #EHA2023 | Laura Pasqualucci @Columbia talks about molecular pathogenesis in diffuse large B cell #lymphoma. Over 80 hypermutated super-enhancers are identified that display AID hallmarks & are frequently linked to B cell regulators & lymphoma oncogenes.
#lym #lymsm

X post image

9 Jun 2023

With all of the exciting content being shared at #EHA2023, the Lymphoma Hub and our steering committee have provided a list of top abstracts to look out for in #lymphoma.

Check it out 👇

https://t.co/qEq9CC18Li

#leusm #cancertreatment #hematology

X post image

9 Jun 2023

One hour to go! Don’t miss out on our CAR-T event today at #EHA2023.

Join us live at 16:15–17:45 CEST

Expert opinions on CAR-T in #multiplemyeloma and #lymphoma, real patient cases, and challenges!

⭐1 credit EBAH accreditation! ⭐

#lymsm #mm

X post image

2 Jun 2023

One week to go! Join us in-person or online at #EHA2023 (16:15 CEST) to gain 1 EBAH credit!

📚The ins and outs of #CART cells in the real world. An expert roundtable hosted by the #Lymphoma Hub and the #MultipleMyeloma Hub📚

Visit the @ESHaematology booth (A124) for more info!

X post image

31 May 2023

Don’t miss out! On June 9, check out our CAR-T program at #EHA2023!

Discussions include:

🟢Biomarkers and CAR T-cell therapy eligibility in #multiplemyeloma and #DLBCL
🟢Real-world patient cases
🟢Answers to common challenges

Visit our page: https://t.co/lzcC6wvEOm

X post image

26 May 2023

Curious about #CART? Join our interactive, open-table discussion on CAR T-cell therapy at #EHA2023!

🟢Ulrich Jager (Chair)
🟢Kieron Dunleavy
🟢Shaji Kumar
🟢Doris Hansen
🟢Michael Hudecek

Visit our page: https://t.co/lzcC6wvEOm

#lymsm #mmsm

X post image

15 May 2023

💭What: The ins and outs of CAR T cells in the real world. An expert roundtable hosted by the Lymphoma Hub and the Multiple Myeloma Hub
📍Where: Frankfurt, Germany & Online
📅When: 16:15–17:45 CEST| 09 June

EBAC accreditation applied for!

#EHA2023 #lymsm #mmsm

#EHA2023

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EHA 2023 European Hematology Association

This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.

Your opinion matters

When selecting the next therapy for patients with R/R MCL after BTKi progression, what is your most important consideration?

Newsletter

Subscribe to get the best content delivered to your inbox